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MicroRNA-199b Modulates Vascular Cell Fate
During iPS Cell Differentiation by Targeting the
Notch Ligand Jagged1 and Enhancing VEGF
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ABSTRACT
Aims: Recent ability to derive endothelial cells (ECs) from induced pluripotent stem (iPS) cells
holds a great therapeutic potential for personalized medicine and stem cell therapy. We aimed
that better understanding of the complex molecular signals that are evoked during iPS cell dif-
ferentiation toward ECs may allow speciﬁc targeting of their activities to enhance cell differen-
tiation and promote tissue regeneration. Methods and Results: In this study, we have generated
mouse iPS cells from ﬁbroblasts using established protocol. When iPS cells were cultivated on
type IV mouse collagen-coated dishes in differentiation medium, cell differentiation toward vas-
cular lineages were observed. To study the molecular mechanisms of iPS cell differentiation, we
found that miR-199b is involved in EC differentiation. A step-wise increase in expression of miR-
199 was detected during EC differentiation. Notably, miR-199b targeted the Notch ligand JAG1,
resulting in vascular endothelial growth factor (VEGF) transcriptional activation and secretion
through the transcription factor STAT3. Upon shRNA-mediated knockdown of the Notch ligand
JAG1, the regulatory effect of miR-199b was ablated and there was robust induction of STAT3
and VEGF during EC differentiation. Knockdown of JAG1 also inhibited miR-199b-mediated inhi-
bition of iPS cell differentiation toward smooth muscle markers. Using the in vitro tube forma-
tion assay and implanted Matrigel plugs, in vivo, miR-199b also regulated VEGF expression and
angiogenesis. Conclusions: This study indicates a novel role for miR-199b as a regulator of the
phenotypic switch during vascular cell differentiation derived from iPS cells by regulating critical
signaling angiogenic responses. STEM CELLS 2015;33:1405–1418
INTRODUCTION
Induced pluripotent stem (iPS) cells are able to
differentiate into nearly all types of cells [1–3].
This unique characteristic offers signiﬁcant
potential for cell-replacement therapies to
repair tissues or organs damaged by injury,
degenerative diseases, aging, or cancer [4–6].
Moreover, the generation of patient-speciﬁc iPS
cells offers a promising strategy for autologous
cell therapy and personalized medicine [7–9].
iPS cells have been extensively used for genera-
tion of endothelial cells (ECs) for in vitro and in
vivo studies [2, 10, 11]. iPS cells can serve as a
very useful tool in establishing efﬁcient proto-
cols of differentiation and developing the plat-
forms to investigate their underlying
mechanisms. Since stem cells need to respond
to a multitude of extrinsic signals to initiate dif-
ferentiation, they are intricately connected with
their surroundings and receive constant input
from their niches, which direct their subsequent
behavior [12, 13]. Therefore, better understand-
ing of the cellular players and molecular signals
that constitute stem cell niches under different
physiological and pathological conditions will
facilitate development of more reﬁned models
of stem cell responses. Subsequently, this may
ultimately allow speciﬁc targeting of their activ-
ities to promote tissue regeneration. For
instance it is speculated that if information
regarding chromatin states with global views of
noncoding RNAs and their regulatory signaling
are combined, it is possible to obtain an integra-
tive picture of the molecular mechanisms that
govern cell fate speciﬁcation.
The molecular switches and regulatory
pathways that control iPS differentiation to ECs
are complex. For example, a number of studies
have demonstrated the critical role of micro-
RNAs (miRNAs) in regulating EC and smooth
muscle marker (SMC) function [14–18]. miRNAs
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are a novel class of short (22 nucleotides) noncoding RNAs,
which are important post-transcriptional inhibitors of gene
expression via base pairing with the three untranslated regions
(UTRs) of mRNAs and promoting mRNA instability [19]. Evi-
dence has emerged about the crucial involvement of speciﬁc
miRNAs in the differentiation of pluripotent stem cells into dif-
ferent lineages. One of the miRNAs that have been shown to be
implicated in myocardial disease is, for example, miR-92a (a
component of the highly expressed in human ECs “miR-
17approximately92” cluster), which controls new blood vessel
formation [8]. In the context of vascular disease, the miRNA
family containing miR-199a-1, miR-199a-2, and miR-199b are
potentially important. Encoded by the intron antisense strand
of a dynamin gene (Dnm2, Dnm3, and Dnm1, respectively) [9]
these miRNAs have been implicated in a number of disease
processes [13]. Importantly, miR-199b is modulated in cardio-
myocytes and ECs by exposure to hypoxia and high glucose in
vitro [20]. To date, several studies have demonstrated the regu-
lation of miRNAs in a myriad of vascular biology events. Never-
theless, there is still insufﬁcient evidence to demonstrate how
they control EC fate commitment and the mechanisms involved
in these differentiation processes.
In this study, we provide evidence that miR-199b is impli-
cated in EC differentiation derived from iPS cells by modulat-
ing vascular endothelial growth factor (VEGF) expression
under transcriptional control of STAT3. To shed light on the
underlying mechanisms of this regulation in iPS cell-derived
ECs, we have shown that miR-199b regulates STAT3-VEGF by
targeting the Notch ligand JAG1. Notably, miR-199b also con-
trols iPS cell differentiation toward SMCs through targeting of
JAG1. We therefore propose a novel role for miR-199b as a
potential regulator of the phenotypic switch during vascular
cell differentiation.
MATERIALS AND METHODS
Materials
Cell culture media, serum, and cell culture supplements were
purchased from ATCC; Manassas, VA, USA, Millipore; USA,
Invitrogen; NY, USA, and PAA; North America. Antibodies
against VE-cadherin (ab33168), Flk-1 (ab9530), VEGFA
(ab51745), STAT3 (ab119351), JAG-1 (ab7771), NOTCH-1
(ab27526), SMA; Smooth Muscle Actin (ab5831), and SM22
(ab14106) were purchased from Abcam; Cambridge, UK. The
Antibody against GAPDH (sc-25778) was purchased from Santa
Cruz. Antibodies against CD31 were purchased from ABBIO-
TEC; San Diego, USA (250590) and Santa Cruz; Heidelberg,
Germany (sc-1506). The secondary antibodies for immuno-
staining anti-mouse Alexa 488 and anti-rabbit Alexa 488 were
purchased from Invitrogen. The secondary antibodies for
Western blotting were purchased from DakoCytomation;
Glostrup, Denmark and Abcam. Recombinant mouse VEGF
was purchased from R and D Systems; Abingdon, UK.
iPS Cell Culture and Differentiation
Mouse iPS cells were generated in our laboratory as previously
described [21]. Mouse iPS cells were cultured on gelatin-coated
ﬂasks (phosphate-buffered saline [PBS] containing 0.04% of gel-
atin from bovine skin; Sigma) in Dulbecco’s modiﬁed Eagle’s
medium (ATCC) supplemented with 10% fetal bovine serum,
100 IU/ml penicillin, and 100 mg/ml streptomycin (Invitrogen);
10 ng/ml recombinant human leukemia inhibitory factor (Milli-
pore); and 0.1 mM 2-mercaptoethanol (Invitrogen) in a humidi-
ﬁed incubator supplemented with 5% CO2. The cells were
passaged every 2 days at a ratio of 1:6. Differentiation of iPS
cells was induced by seeding the cells on type IV mouse colla-
gen (5 mg/ml)-coated dishes in differentiation medium (DM)
that contains a-MEM supplemented with 10% fetal bovine
serum (FBS) (Invitrogen), 0.05 mM 2-mercaptoethanol, 100
units/ml penicillin, and 100 mg/ml streptomycin in the presence
of with 50 ng/ml VEGF from 0 to 8 days.
Jag1 Substrate
Mouse iPS cells were seeded on 5 mg/ml Jag-1-coated
plates and cultured in DM media supplemented with VEGF
for 6 days. Then the cells were harvested and subjected to
further analysis and the expression of EC markers were
detected by real-time PCR. The Recombinant Rat Jagged 1
FC Chimera, (Product Code: 599-JG100) was purchased from
R&D Systems and prepared according to the manufacturer’s
instructions.
miR-199b Transient Transfection
Manipulation of miR-199b levels in iPS cells differentiated in
the presence of VEGF for 4 days and cultured to 60%–70% con-
ﬂuence was performed using a synthetic precursor for miR-
199b (Pre-199b), or the nontargeting control (Pre-ctrl) (Ambion
AB), whereas inhibition of miR-199b was performed using the
locked nucleic acid (LNA) inhibitor of miR-199b (LNA-199b) or a
negative control (LNA-ctrl) (Exiqon). All transfections have been
performed using Lipofectamine RNAiMAX (Invitrogen), at a ﬁnal
concentration of 50 nM, according to the manufacturer’s proto-
col. All these experiments have been performed in the pres-
ence of the VEGF from day 0 to days 6–7, where the
transfected cells were harvested and subjected to further anal-
ysis. In order to highlight the important role of miR-199b in the
secretion of the VEGF and EC differentiation, few experiments
have been designed and performed in the absence of VEGF. All
the experimental conditions have been clearly described in the
methods, the results, and the ﬁgure legends. To detect miRNAs,
total RNA was isolated using the miRVana miRNA isolation kit
(Ambion) according to the protocol of the manufacturers. Total
and miRNA-speciﬁc cDNA was generated with TaqMan Micro-
RNA Reverse Transcription Kit (Ambion), and miRVana quantita-
tive reverse transcriptase-polymerase chain reaction (RT-PCR)
primer sets for miRNAs (Ambion). The PCR reaction was directly
monitored by the ABI PRISM 7000 Sequence Detection System
(Applied Biosystems, CA). Brieﬂy, cDNA was made from
enriched miRNA using the TaqMan MicroRNA RT Kit. U6 RNA
was also used as an endogenous control.
Reverse Transcriptase-Polymerase Chain Reaction
RT-PCR and real-time PCR were performed as described previ-
ously [22]. The detailed method is shown in Supporting Infor-
mation Methods S1.
Quantitative RT-PCR
Relative gene expression was determined by quantitative real-
time PCR, using 2 ng of cDNA (relative to RNA amount) for
each sample with the SYBR Green Master Mix in a 20-ml reac-
tion. Ct values were measured using the ABI Prism 7000
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sequence detector (Applied Biosystems). The 18 S ribosomal
RNA served as the endogenous control to normalize the
amounts of RNA in each sample. For each sample, PCR was
performed in duplicate in a 96-well reaction plate (Eppendorf,
twin.tec real-time PCR plates). The gene was considered unde-
tectable beyond 35 cycles. A primer list is given in Supporting
Information Methods S1.
Immunofluorescence Staining
The procedure used for immunoﬂuorescent staining was simi-
lar to that described previously [22]. Brieﬂy, cells were ﬁxed
with 4% paraformaldehyde and permeabilized with 0.1% Tri-
ton X-100 in PBS for 10 minutes and blocked in 5% swine
serum in PBS for 30 minutes at 37C. The cells were incu-
bated with primary antibody: mouse VEGFR (Flk-1) or rabbit
CD144 for 1 hour at 37C. The bound primary antibody was
revealed by incubation with the secondary antibody; anti-
mouse Alexa488, or anti-rabbit Alexa488 at 37C for 30
minutes. Cells were counterstained with 40,6-diamidino-2-phe-
nylindole (DAPI; Sigma), mounted in Floromount-G (Cytoma-
tion; DAKO, Glostrup, Denmark), and examined with a
ﬂuorescence microscope (Axioplan 2 imaging; Zeiss) or SP5
confocal microscope (Leica, Germany).
Immunoblotting
The method used was similar to that described previously
[22]. The detailed method is present in Supporting Informa-
tion Methods S1.
Lentiviral Particle Transduction
Lentiviral particles were produced using the MISSION
shSTAT3, shJAG-1 DNA plasmids (SIGMA) according to proto-
col provided and previously described [22]. The shRNA Non-
targeting vector was used as a negative control. For lentiviral
infection, iPS were differentiated for 3 days, and the cells
were incubated with shSTAT3, or shJAG-1 or Nontargeting
control (1 3 107 TU/ml) (24 hours prior the transfection with
mir-199b or inhibitor), in complete medium supplemented
with 10 mg/ml of Polybrene for 24 hours. Subsequently, fresh
medium was added to the cells and the plates were returned
to the incubator and harvested 72 hours later for further
analysis. The detailed method is shown in Supporting Infor-
mation Methods S1.
Luciferase Reporter Assay
For the luciferase reporter assays, 3 3 104 iPS cells were
seeded on collagen IV-coated well of a 12-well plate in DM
containing VEGF. Seventy-two hours later, cells were trans-
fected with the luciferase plasmids under the control of the
promoter of the VEGF receptor (Addgene [plasmid 21307]
generated by Mammoto et al.) [23], the JAG1 30UTR Lenti-
reporter-Luc Vector (ABM), and the Pre-199b, LNA-199b and
controls. Brieﬂy, 0.33 mg/well of the reporter plasmids was
cotransfected with the Pre-199b, or LNA-199b and controls (2
ml/well) using jetPRIME (Polyplus-transfection SA) according to
the protocol provided. pGL3-Luc Renilla (0.1 mg/well) was
included in all transfection assay as internal control. Luciferase
and Renilla (Promega) activity assays were detected 48 hours
after transfection using a standard protocol [24]. The relative
luciferase unit was deﬁned as the ratio of luciferase activity
to Renilla activity with that of control set as 1.0.
Enzyme-Linked Immunosorbent Assay
The concentration of the VEGF released in the supernatant
was detected by VEGF ELISA kit (R&D) according to the
manufacturers’ procedure. Differentiation of iPS cells was
induced by seeding the cells on type IV mouse collagen-
coated dishes in DM media supplemented with VEGF. On
day 4th, the cells were transfected with Pre-199b or LNA-
199b and the relative controls (Pre-Ctrl, LNA-Ctrl), and 48
hours later, the supernatant have been collected and the
secretion of VEGF was quantiﬁed by enzyme-linked immuno-
sorbent assay (ELISA) according to the manufacturer’s
instructions.
Fluorescence-Activated Cell Sorting Analysis
iPS cells were seeded on type IV mouse collagen-coated
dishes in DM media supplemented with VEGF. On day 4th,
the cells were transfected with Pre-199b or LNA-199b and the
relative controls (Pre-Ctrl, LNA-Ctrl). Forty-eight hours later,
the cells were harvested and subjected to ﬂuorescence-
activated cell sorting (FACS) analysis for CD31-FITC (ab13466),
rabbit anti-IgG-FITC, CD144-FITC (ab33321, Abcam), SMA (Cy3
[C6198], SIGMA), and IgG-Cy3 (C2181, Sigma) using a similar
protocol as it has been previously described [24]. Where an
intracellular staining was performed such as intracellular anti-
gen for SMA, the cells were incubated with cold permeabiliza-
tion buffer (PBS-0.1% Triton X-100) for 15 minutes on ice,
before the nonspeciﬁc antibody binding blocking and primary
antibody incubation steps. Data analysis was carried out using
Attune Cytometric Software.
In Vitro Tube Formation Assay
iPS cells were seeded on collagen IV-coated plates and cul-
tured in DM media in the absence of VEGF for 4 days, then
the Pre-199b or Pre-Ctrl was introduced to the cells by trans-
fection (in the absence of VEGF). Forty-eight hours later, the
cells have been subjected to Matrigel plugs assays in vitro.
Additional experiments were performed in the presence of
the VEGF to induce EC differentiation ﬁrst and then the cells
were transfected with LNA-199b or LNA-Ctrl. Forty-eight hours
later, the cells have been subjected to Matrigel plugs assays
in vitro. In vitro angiogenesis assays were performed after 48
hours as described previously [21, 24]. Cell suspension con-
taining 4 3 104 transfected cells was placed on top of the 50
ml/well Matrigel (10 mg/ml; BD Matrigel Basement Membrane
Matrix, A6661) in eight-well chamber slides (Nunc). Rear-
rangement of cells and formation of capillary-like structures
were observed at 6–12 hours.
In Vivo Angiogenesis Assay
iPS cells were differentiated and transfected as described
above for in in vitro tube formation assays. Forty-eight hours
later, the cells were labeled with Molecular Probes Vybrant
Cell Labeling (MP22885) before the in vivo angiogenesis
assay in order to distinguish the in vitro-differentiated cells
from the host cells. In vivo angiogenesis was performed by
mixing 5 3 105 cells with 200 ml of Matrigel and injecting it
subcutaneously in mice (C57BL/6). Six injections were con-
ducted for each group. Seven days later, the mice were
killed and the plugs were harvested, frozen in liquid nitro-
gen, and cryosectioned. Samples were ﬁxed with 4%
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Figure 1. MiR-199b is implicated in EC differentiation derived from iPS cells. (A): Mouse iPS cells were seeded on collagen IV-coated
dishes and cultured in differentiated media supplemented with 50 ng/ml vascular endothelial growth factor (VEGF). Images show the
morphology of undifferentiated iPS cells (left panel), differentiated into ECs (iPS-ECs) on day 8 (middle panel), and immunoﬂuorescent
images of CD144-positive iPS-ECs on day 8 during EC differentiation. DAPI was used and stained the cell nucleus. Scale bar5 50 mm.
(B): The endothelial markers CD31 and CD144 are induced in a time point manner during EC differentiation from iPS cells in the mRNA
level as real-time PCR experiments demonstrated (data are means6 SEM; n5 3), *, p< .05. (C): The expression of miR-199b was found
to be upregulated during EC differentiation in a time point experiment as real-time PCR revealed (data are means6 SEM; n5 3), *,
p< .05. (D): iPS cells were forced to differentiate toward ECs for 4 days by seeding the cells on collagen IV in the presence of differen-
tiation medium supplemented with VEGF and then efﬁciently transfected with either Pre-199b precursor molecules (Pre-199b) or an
miR-199b inhibitor (LNA-199b) resulted in signiﬁcant Pre-199b upregulation and miR-199b repression, respectively (D). On day 7, the
cells were harvested and further analyzed, revealing that Pre-199b increased the expression of endothelial markers CD144 and CD31 in
both protein (E, F [quantiﬁcation]) and mRNA levels as it is shown by real-time PCR (I). LNA-199b decreased the EC marker expression
in protein (E, F) and mRNA levels (I) (data are means6 SEM; n5 3), *, p< .05. (G, H): Fluorescence-activated cell sorting analysis was
performed and conﬁrmed that Pre-199b induced the expression of EC markers CD31, and CD144 during EC differentiation. (J): Immuno-
ﬂuorescence images showed that Pre-199b induced the expression of VEGF receptor 2 (FLK-1), scale bar5 50 mm, and 25 mm (insets).
The data presented were representative or average of three independent experiments. Abbreviations: DAPI, 40,6-diamidino-2-phenylin-
dole; ECs, endothelial cells; iPS, induced pluripotent stem; LNA-199b, locked nucleic acid inhibitor of miR-199b; LNA-Ctrl, a negative con-
trol; Pre-199b, a synthetic precursor for miR-199b; Pre-ctrl, the nontargeting control.
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paraformaldehyde in PBS at 4C overnight, and then HE
staining was performed at room temperature, and were
processed with Photoshop software (Adobe). Images were
assessed with Axioplan 2 imaging microscope with Plan-
NEOFLUAR 310, NA 0.3, objective lenses, AxioCam camera,
and Axiovision software (all Carl Zeiss MicroImaging, Inc.) All
procedures were performed according to protocols approved
by the Institutional Committee for Use and Care of Labora-
tory Animals. All animals used in this study were inbred
mice of C57BL/6 background.
Immunofluorescence Staining and Frozen Section
Staining
The procedure for frozen section staining is similar to that
described elsewhere [25]. In short, Matrigel plugs were har-
vested, serial 5-mm-thick frozen sections were cut from
Figure 1. Continued
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Figure 2. MiR-199b modulates VEGF transcriptional activation and secretion though STAT3. (A): Induced pluripotent stem (iPS) cells
were forced to differentiate toward endothelial cells (ECs) for 4 days by seeding the cells on Collagen IV and culture with differentiation
medium in the presence of VEGF and then transfected with either Pre-199b or LNA-199b and luciferase reporter plasmid for the VEGF
receptor. Forty-eight hours later, the cells were lysed and luciferase assays showed that Pre-199b modulates the transcriptional activa-
tion of VEGF receptor. (B): Enzyme-linked immunosorbent assays demonstrated that the Pre-199b is implicated in the secretion of VEGF
during EC differentiation from iPS cells on day 6. (C, D): Pre-199b induced the expression of VEGF in both protein and mRNA levels in
parallel with the expression levels of STAT3. Conversely, LNA-199b signiﬁcantly suppressed the expression of VEGF and STAT3, as West-
ern blots and real-time PCRs showed, respectively. (E): iPS cells were forced to differentiate toward ECs, and when STAT3 was knocked
down by shRNA, Pre-199b was unable to induce the expression of VEGF and subsequently the EC marker expression CD144 and CD31
and (F, quantiﬁcation) (data are means6 SEM [n5 3], *, p< .05). The data presented were representative or average of three independ-
ent experiments. Abbreviations: LNA, locked nucleic acid; shNT, short hairpin RNA nontargeting; shSTAT3, short hairpin RNA STAT3; VEGF,
vascular endothelial growth factor.
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cryopreserved tissue blocks, ﬁxed in a cold 1:1 acetone 10
minutes, and washed with PBS for 20 minutes. After wash-
ing with PBS, specimens were placed in a humidiﬁed cham-
ber and blocked in 5% swine serum in PBS for 30 minutes
at 37C and incubated with primary antibodies rabbit anti-
VE-cadherin and rabbit anti-CD31 and proceed as described
in the immunostaining section above. The bound primary
antibodies were revealed by incubation with the secondary
antibody; anti-rabbit Alexa488, at 37C for 30 minutes.
Specimens were counterstained with DAPI (Sigma), mounted
in Floromount-G (Cytomation; DAKO), and EC markers, DAPI
and Vybrant were examined with a ﬂuorescence microscope
(Axioplan 2 imaging; Zeiss) or SP5 confocal microscope
(Leica, Germany). Immunostaining was assessed and capillary
Figure 3. MiR-199b targets the Notch ligand Jagged1. Pre-199b suppressed the expression of Notch ligand Jagged1 (JAG1) (A) and sub-
sequently the Notch 1 (B) in mRNA and protein levels (C, and quantiﬁcation in D) during endothelial cell (EC) differentiation from induced
pluripotent stem (iPS) cells (data are means6 SEM [n5 3], *, p< .05). LNA-199b induced the expression of both JAG1 and Notch (A–D).
(E): iPS cells were forced to differentiate toward ECs for 4 days, and cotransfections of Pre-199b or LNA-199b with the luciferase plasmid
of the 30UTR-JAG1 were performed. Forty-eight hours later, the cells have subjected to luciferase analysis demonstrating that the 30UTR
of the JAG1 is a direct target of miR-199b (data are means6 SEM [n5 3], *, p< .05). The data presented were representative or average
of three independent experiments. Abbreviations: LNA, locked nucleic acid; 30UTR, three prime untranslated region.
Chen, Margariti, Kelaini et al. 1411
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density was calculated as the number of capillary number/
mm2.
Statistical Analysis
Data expressed as the mean6 SEM were analyzed using Graph-
Pad Prism 5 software with a two-tailed Student’s t test for two
groups or pairwise comparisons. A value of p< .05 was consid-
ered signiﬁcant; signiﬁcance was depicted by asterisks, *, p< .05.
RESULTS
MiR-199b Is Implicated in EC Differentiation Derived
from iPS Cells
In this study, mouse iPS cells were generated and differenti-
ated into EC-like cells as described previously [21]. In brief,
undifferentiated mouse iPS cells (Fig. 1A, left panel) were sub-
jected to differentiation by seeding the cells on type IV mouse
Figure 4. MiR-199b modulates STAT3-VEGF activation through targeting JAG1. Mouse induced pluripotent stem (iPS) cells were seeded
on 5 mg/ml Jag-1-coated plates and cultured in differentiation medium (DM) supplemented with vascular endothelial growth factor
(VEGF) for 6 days. Then the cells have been harvested and subjected to further analysis and the expression of endothelial cell (EC)
markers were detected by real-time PCR. (A): The differentiated cells in Jag1-mediated substrate signiﬁcantly reduced the expression of
EC marker CD144, the expression of VEGF and VEGF receptor (FLK-1), when compared with the control experiments (cells seeded on
collagen IV-coated dishes) (data are means6 SEM [n5 3], *, p< .05) at day 6 during EC differentiation. Control: iPS cells seeded on col-
lagen IV-coated dishes, Jag1 Substrate: the recombinant rat Jagged 1 FC Chimera (Product Code: 599-JG100). (B): iPS cells were forced
to differentiate toward ECs on collagen IV-coated dishes in DM media supplemented with VEGF and the JAG1 was knocked down by
shRNA. Then, the inhibitory effect of the LNA-199b inhibitor in EC markers and VEGF and VEGFR (FLK-1) was ablated in both mRNA (B)
and protein levels (C), and quantiﬁcation in (D). Knockdown of JAG1 by shRNA during EC differentiation showed a robust induction of
STAT3 and VEGF in the presence of the miR-199b inhibitor in protein level as displayed by Western blots (C, D) (data are means6 SEM
[n5 3], *, p< .05). The data presented were representative or average of three independent experiments. Abbreviations: LNA, locked
nucleic acid; shJAG1, short hairpin RNA JAG1; shNT, short hairpin RNA nontargeting.
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collagen-coated dishes in DM supplemented with 50 ng/ml
VEGF from 0 to 8 days. The differentiated cells acquired a typ-
ical morphology of ECs (Fig. 1A, middle panel) and started
expressing EC markers such as CD144 and CD31 in both pro-
tein (Fig. 1A, right panel), and mRNA levels (Fig. 1B). During
EC differentiation, the expression levels of miR-199b were
tested and found to be upregulated in a time-dependent
manner (0–8 days). Notably, enhanced expression of miR-
199b was detected in the late stages of EC differentiation
(day 8) (Fig. 1C). To elucidate the regulatory role of miR-199b
in EC differentiation, a synthetic precursor for miR-199b (Pre-
199b) was used to overexpress miR199b. iPS cells were forced
to differentiate toward ECs for 4 days and then efﬁciently
transfected with either precursor molecules (pre-199b) or the
chemically synthesized miR-199b inhibitor (LNA-199b). The
cells were harvested 48–72 hours later, and subjected to fur-
ther analysis. The results revealed a signiﬁcant upregulation
and diminution of miR-199b expression, respectively (Fig. 1D).
The Pre-199b induced enhanced expression of the EC markers
CD144 and CD31 in both protein and mRNA levels (Fig. 1E,
1F, and Supporting Information Fig. S1). These results were
also conﬁrmed by FACS analysis (Fig. 1G–1H) and real-time
PCR (Fig. 1I). Conversely, knockdown of miR-199b by LNA-
199b signiﬁcantly decreased the EC marker expression in both
protein (Fig. 1E, 1F, and Supporting Information Fig. S1), and
mRNA levels (Fig. 1I). Importantly enhanced Pre-199b expres-
sion resulted in a concomitant rise in VEGF receptor 2 (FLK-1)
as immunoﬂuorescence staining images show in Figure 1J.
These initial observations reveal an important role of miR-
199b in EC differentiation derived from iPS cells.
Figure 5. MiR-199b may have a role as a phenotypic switch in vascular cell differentiation. Induced pluripotent stem (iPS) cells were
seeded on collagen IV-coated dishes and cultured with differentiated media in the absence of vascular endothelial growth factor for 4
days and forced to differentiate toward vascular progenitor cells. (A) Overexpression of Pre-199b suppressed the expression of smooth
muscle markers (SMCs) such as SMA and SM22 in mRNA (A) and protein levels (B), as real-time and Western blots showed, respectively,
on day 6 during the vascular cell differentiation. LNA-199b favored the induction of the SMC markers (A, B). (C): When iPS cells were
forced to differentiate toward vascular progenitor cells and JAG-1 was knocked down by shRNA on day 4, a signiﬁcant suppression of
SMCs markers such as SMA and SM22 in mRNA and protein levels is shown in panels (C) and (D) (data are means6 SEM [n5 3], *,
p< .05), on day 6 of differentiation. The data presented were representative or average of three independent experiments. Abbrevia-
tions: LNA, locked nucleic acid; shJAG1, short hairpin RNA JAG1; shNT, short hairpin RNA nontargeting.
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MiR-199b Modulates VEGF Transcriptional Activation
and Secretion
VEGF is a critical regulator of EC differentiation and vasculo-
genesis during development. Additional experiments have
been performed to investigate the potential role of miR199b
in VEGF transcriptional activation and secretion. Mouse iPS
cells were differentiated toward ECs in the presence of VEGF
for 4 days, and then transfected with Pre-199b or Pre-Ctrl,
and LNA-199b or LNA-Ctrl. Forty-eight, and seventy-two hours
later, the cells were subjected to luciferase assays, and super-
natants were collected and ELISA assays were performed. The
results have revealed that Pre-199b modulated the transcrip-
tional activation of VEGF receptor as determined by luciferase
assays (Fig. 2A). Furthermore, induced expression or suppres-
sion of miR-199b signiﬁcantly enhanced or impaired transcrip-
tional activation and secretion of VEGF (Fig. 2A, 2B). Among
the transcription factors essential to VEGF gene transcription
are the hypoxia-inducible factor-1, Sp1, and STAT3 which
share homology including consensus sites for Sp1/Sp3, AP2,
Egr1, STAT3, and HIF1. It was demonstrated that Pre-199b
induced the expression of VEGF in both protein and mRNA
levels in parallel with the expression levels of STAT3 (Fig. 2C,
2D). Conversely, in the presence of the LNA-199b, both VEGF
and STAT3 expression were signiﬁcantly reduced in both pro-
tein and mRNA levels (Fig. 2C, 2D). In order to investigate
whether miR-199b regulated the VEGF expression through the
activation of the transcription factor STAT3, Pre-199b was
overexpressed during EC differentiation. When STAT3 was
knocked down using shRNA, Pre-199b was unable to induce
expression of VEGF or EC markers (Fig. 2E, 2F). These ﬁndings
highlight the regulatory role of miR-199b in VEGF expression
which is mediated, at least in part, through transcriptional
activation of STAT3.
MiR-199b Targets the Notch Ligand Jagged1
The Notch pathway is a highly conserved signaling system
that controls a diversity of growth, differentiation, and pat-
terning processes. In growing blood vessels, sprouting of
endothelial tip cells is inhibited by Notch signaling and the
precise equilibrium between two Notch ligands with distinct
spatial expression patterns and opposing functional roles reg-
ulates angiogenesis. Interestingly, further experiments have
demonstrated that the Pre-199b suppressed the expression
of JAG1 and Notch 1 while the LNA-199b induced the
expression of both JAG1 and Notch 1 (Fig. 3A–3D). In addi-
tion, luciferase assays revealed that the 30UTR of the JAG1 is
a direct target of Pre-199b during EC differentiation from iPS
cells (Fig. 3E). These ﬁndings suggest that miR-199b targets
the Notch ligand JAG1 during differentiation toward ECs
derived from iPS cells.
MiR-199b Modulates STAT3-VEGF Activation Through
Targeting JAG1
In order to investigate whether JAG-1 is involved in EC differ-
entiation, mouse iPS cells were seeded on JAG1 substrate and
cultured in DM media supplemented with VEGF to induce EC
differentiation. It was revealed that the JAG1-mediated sub-
strate signiﬁcantly reduced the expression of CD144, VEGF,
and the VEGF receptor (FLK-1) during EC differentiation (Fig.
4A). Importantly, when JAG1 was knocked down by shRNA,
the inhibitory effect of LNA-199b was ablated (Fig. 4B, 4C).
Notably, knockdown of JAG1 resulted in the robust induction
of STAT3 and VEGF in the presence of LNA-199b (Fig. 4C, 4D).
These results suggest that miR-199b modulates STAT3-VEGF
activation through targeting JAG1.
MiR-199b May Act as a Phenotypic Switch in Vascular
Cell Differentiation
In parallel with the EC experiments, Pre-199b also served in
suppressing the expression of VSMC markers SMA and SM22
Figure 6. MiR-199b induced angiogenesis in vitro. Induced pluri-
potent stem cells were seeded on collagen IV-coated plates and
cultured in differentiation medium in the absence of vascular
endothelial growth factor (VEGF) for 4 days, then the Pre-199b or
Pre-Ctrl was introduced to the cells by transfection (in the
absence of VEGF). Forty-eight hours later, the cells have been
subjected to Matrigel plug assays in vitro. (A): It is shown that
Pre-199b formed vascular structures within few hours in in vitro
Matrigel assays in comparison to the control where less deﬁned
vascular structures were observed (A, top panel, and quantiﬁca-
tion in B) (scale bar5 50 mm). Additional experiments were per-
formed in the presence of the VEGF to induce endothelial cell
differentiation ﬁrst and then LNA-199b was introduced by trans-
fection, showing that the LNA-199b suppressed the formation of
vascular structures in in vitro Matrigel plugs assays in comparison
to the control cells (A, lower panel, and quantiﬁcation in B) (scale
bar5 50 mm) (data are means6 SEM [n5 3], *, p< .05). The
data presented were representative or average of three inde-
pendent experiments. Abbreviation: LNA, locked nucleic acid.
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during differentiation from iPS cells (Fig. 5A, 5B), when iPS
cells were seeded on Collagen IV and cultured in DM media
in the absence of VEGF. Conversely, the LNA-199b favored the
induction of the SMC markers (Fig. 5A, 5B). Further support
to this notion has been given by the fact that knockdown of
JAG1 by shRNA during differentiation toward vascular progeni-
tor cells, resulted in suppression of SMCs markers in mRNA
and protein levels in Figure 5C, 5D, respectively. These results
Figure 7.
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provide a link between miR-199b, the inhibition of JAG1 and
SMC differentiation. Based on the fact that both EC and
VSMCs are derived from a common vascular progenitor, addi-
tional experiments were performed in the presence of VEGF.
Mouse iPS cells were subjected to vascular cells differentia-
tion in DM media supplemented with VEGF and on day 4, the
cells were transfected with Pre-199b or Pre- Ctrl. Forty-eight
hours later, the cells were harvested and FACS analysis was
performed. The results have revealed that Pre-199b induced
the expression of EC markers as shown in Figure 1G, 1H,
whilst in parallel resulted in suppression of the VSMC marker
SMA (Supporting Information Fig. S2A, S2B). These ﬁndings
could suggest that miR-199b might have a potential role to
act as a phenotypic switch during vascular cell differentiation.
MiR-199b Induced Angiogenesis In Vitro and In Vivo
To evaluate the role of miR-199b in angiogenesis, miR-199b
was altered by overexpression using Pre199b or inhibition
using LNA-199b. Since previous results indicated that miR-
199b induced the secretion of VEGF, we decided to perform
the overexpression experiments with Pre-199b in the absence
of exogenous VEGF using Matrigel plug assays in vitro and in
vivo. In brief, mouse iPS cells were seeded on collagen IV-
coated plates and cultured in DM media in the absence of
VEGF for 4 days and the Pre-199b mimic or Pre-Ctrl were
introduced to the cells by transfection. Forty-eight hours later,
the cells were labeled with Vybrant and subjected to Matrigel
assays plugs in vitro and in vivo. Differentiated cells in the
presence of a Pre-199b showed signiﬁcantly enhanced vascu-
lar tube formation in vitro (Fig. 6A, and quantiﬁcation in 6B)
and vessel formation in vivo (Fig. 7A, and quantiﬁcation in Fig.
7B) when compared with Pre-Ctrl. It is important to highlight
that these experiments using Pre-199b or Pre-Ctrl have been
performed in the absence of VEGF and that the enhancement
of vascular tube formation in both in vitro and in vivo results
from the secretion of VEGF by Pre-199b. In order to test
whether inhibition of miR199b by LNA-199b could result in
suppression of vascular tube formation in vitro and in vivo, fur-
ther experiments were performed in the presence of VEGF to
induce EC differentiation ﬁrst following inhibition by LNA-199b.
It was demonstrated that LNA-199b suppressed the formation
of vascular structures in both in vitro and in vivo assays in com-
parison to the LNA-Ctrl cells (Figs. 6A, 7A, and quantiﬁcation in
Figs. 6B, 7B). The Matrigel plugs were harvested from mice 7
days post-transplantation, and subjecting to immunohisto-
chemistry revealing the presence of CD31 and CD144 EC
markers (Fig. 7C–7E). ECs over-expressing Pre-199b displayed
more well-formed vascular structures and enhanced engraft-
ment ability when compared with the control cells (Fig. 7C,
7D). In contrast, differentiated ECs transfected with LNA-199b
displayed reduced vascular formation and engraftment ability
(Fig. 7E). Importantly, the Pre-199b overexpressing cells were
costained positive for the EC markers CD31 and CD144, as well
as Vybrant, revealing that the injected mouse iPS cells formed
the vascular structures in matrigel plugs in vivo (Fig. 7F).
DISCUSSION
iPS cells have the potential to differentiate into any adult cell
and they have already signiﬁcantly impacted the study of dis-
ease and the discovery of potential stem cell-based therapies.
Ultimately, this technology may represent the most attractive
cellular approach for regenerative medicine [1–3]. In this
study, we report that miR-199b is involved in iPS cell differen-
tiation to ECs. MiR-199b is upregulated during EC differentia-
tion, and signiﬁcantly enhanced expression of miR-199b
occurs in the late stages of this process. Notably, miR-199b
targets the Notch ligand JAG1, which results in VEGF tran-
scriptional activation and secretion through the transcription
factor STAT3. Our ﬁndings provide the ﬁrst evidence that miR-
199b regulated Notch signaling is crucial for VEGF production,
which directs iPS cell differentiation toward endothelial
lineages.
MiR-199b has been described as a potential Notch regula-
tor through targeting the transcription factor HES1 [12, 26].
Notch signaling is essential for vascular development, homeo-
stasis, and angiogenesis although the molecular basis for its
upstream regulation remains poorly understood. It has been
previously reported that the Notch ligand Delta-like 4 nega-
tively regulates endothelial tip cell formation and vessel
branching [27]. In this study, miR-199b was shown to induce
the secretion and transcriptional activation of VEGF during EC
differentiation from iPS cells. VEGF is the earliest marker for
the endothelial lineage during development [28, 29]. To shed
light on the underlying mechanisms, it has been revealed that
the activation of VEGF by Pre-199b is mediated, at least in
part, by STAT3 activation. Interestingly, knockdown of STAT3
Figure 7. Modulation of MiR-199b expression induces angiogenesis and expression of endothelial cell (EC) markers in vivo. In a similar
way as in Figure 6, the cells were subjected to Matrigel plug assays in vivo. (A): Mouse induced pluripotent stem (iPS) cells were seeded
on collagen IV-coated plates and cultured in differentiated media in the absence of vascular endothelial growth factor (VEGF) for 4 days
and the Pre-199b or Pre-Ctrl was introduced to the cells by transfection. Forty-eight hours later, the cells were labeled with Vybrant
and subjected to Matrigel plug assays in vivo. It is shown that Pre-199b induced the formation of well-deﬁned vascular structures within
7 days in in vivo Matrigel assays in comparison to the control where less well-formed vascular structures were observed (A, top panel
[scale bar5 50 mm], and quantiﬁcation in B). Mouse iPS cells were seeded on collagen IV-coated plates and cultured in differentiated
media in the presence of VEGF for 4 days to induced EC differentiation ﬁrst and LNA-199b or LNA-Ctrl was introduced to the cells by
transfection. Forty-eight hours later, the cells were labeled with Vybrant and subjected to Matrigel plug assays in vivo. LNA-199b inhibi-
tor suppressed the formation of vascular structures in in vivo Matrigel plugs assays in comparison to the control cells (A, lower panel
[scale bar5 50 mm], and quantiﬁcation in B) (data are means6 SEM [n5 3], *, p< .05). (C, D): Frozen sections were stained with EC-
speciﬁc markers demonstrating that over-expression of Pre-199b resulted in well-formed vascular structures and enhanced engraftment
ability compared to the control cells as staining for CD144 and CD31 showed (scale bar for C; 250 mm, for D; 50 mm and insets in D; 25
mm). DAPI was used and stained the cell nucleus. (E): MiR-199b inhibition by LNA-199b resulting in a reduced vascular formation and
engraftment ability as it is revealed by staining with EC markers, scale bar5 50 mm. Importantly, the Pre-199b overexpressing cells were
positively costained for the EC markers CD31 and CD144 and Vybrant, revealing that the injected mouse iPS cells formed the vascular
structures in matrigel plugs in vivo (F), scale bar5 50 mm (upper panel), 25 mm (lower panel). The data presented were representative
or average of three independent experiments. Abbreviations: DAPI, 40,6-diamidino-2-phenylindole; LNA, locked nucleic acid.
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by shRNA ablated secretion of VEGF and the expression of EC
markers mediated by Pre-199b. It is established that constitu-
tive STAT3 activity upregulates VEGF [30], as STAT3 protein
binds to the VEGF promoter inducing VEGF promoter activity
[30]. Therefore, our data indicate that inhibition of JAG-1 by
Pre-199b leads to activation of STAT3 and induction of EC dif-
ferentiation from iPS cells. In parallel, we found that inhibi-
tion of JAG-1 by Pre-199b leads to the suppression of SMCs
differentiation. In addition, inhibition by LNA-199b resulted in
robust induction of SMC marker expression. Ferreira et al. in
2007 have reported that vascular progenitor cells isolated
from human embryonic stem cells gave rise to EC and SMC-
like cells and formed vascular networks in vivo [6], providing
strong evidence that ECs and SMCs were derived from a com-
mon progenitor. Therefore, it is possible that a molecular
switch could regulate the vascular cell fate and thereby main-
tain the balance of these two cell lineages during develop-
ment, disease-repairing process, and cell differentiation. This
notion is in agreement with a recent study showing that TGF-
beta induced JAG1 and SMC markers, in an independent man-
ner of the activation of SMAD3 and Rho kinase. In the same
study, it was also shown that knocking down JAG1 completely
blocked MYOCD expression, suggesting that this ligand plays
an important role in TGF-beta-induced expression of SMC
markers. Notch activation in human embryonic stem cells sup-
presses appearance of EC markers [31]. Our ﬁndings may sug-
gest a potential unique role of miR-199b as a regulator of
Notch signaling. This may imply a vascular cell phenotypic
switch, possibly suggesting previously unrecognized mecha-
nisms involved in iPS cells differentiation.
This study highlights the potential of Pre-199b in regulat-
ing angiogenesis in both in vitro and in vitro Matrigel plug
assays, even in the absence of exogenous VEGF. In previous
studies, iPS cell-derived ECs incorporated into the regenerat-
ing microvasculature of ischemic tissue, thereby enhancing
perfusion and improving function [32, 33]. Currently, the
potential of human iPS cells to differentiate toward thera-
peutic cells is based on directed empiricism. They are also
entirely dependent on combinations of growth factors,
media, and matrices to favor the desired lineage. In regards
to vascular regeneration, it is important to understand regu-
latory pathways such as epigenetic alterations, transcriptional
activity, and microRNA patterns associated with the differen-
tiation processes. Only then, reﬁned experimental protocols
may reproducibly guide human iPS cells to a vascular lineage
[34, 35] and enable clinical application [36–38]. In this
regard, the role of miR-199b during human iPS cells differen-
tiation toward ECs has been evaluated and preliminary data
showed that Pre-199b induced further EC marker expression
during EC differentiation derived from human iPS cells. In
contract, LNA-199b resulted in the inhibition of EC differen-
tiation (Supporting Information Fig. S3). These results con-
ﬁrm the potential role of miR-199b in EC differentiation
derived from human iPS cells as well.
In summary, our data strongly support the notion that
miR-199b modulates VEGF transcriptional activation and
secretion through STAT3 and JAG1. Notably, further elucida-
tion of the underlying mechanisms has revealed that through
targeting of JAG1, miR-199b inhibited the differentiation
toward SMCs (Supporting Information Fig. S4). This points
toward a novel role for miR-199b as a potential regulator of
the phenotypic switch during vascular cell differentiation.
Finally, the effect of miR-199b to secrete VEGF and induce
angiogenesis has been evaluated in in vitro and in vivo Matri-
gel plug assays. This study provides support to the notion that
with diligent efforts to understand the molecular mechanisms
of vascular cell fate, stem cell regenerative therapy may ulti-
mately become a reality and shift the paradigm to treat cardi-
ovascular disease.
CONCLUSIONS
This study provides support to the notion that with diligent
efforts to understand the molecular mechanisms of vascular
cell fate, stem cell regenerative therapy may ultimately
become a reality and shift the paradigm to treat cardiovascu-
lar disease.
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